VivoSeq
Other

Moderate Hepatic Impairment

1

Pipeline Programs↗

6

Active Trials↗

31

Companies Involved↗

Moderate Hepatic Impairment is an early-stage landscape with 1 program across 31 companies. The most active players are AstraZeneca, Merck & Co., Vertex Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

25/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 1Merck & Co. logo

Merck & Co.

0 programs

PreclinicalVertex Pharmaceuticals logo

Vertex Pharmaceuticals

0 programs

PreclinicalAstellas logo

Astellas

0 programs

PreclinicalEisai logo

Eisai

0 programs

PreclinicalNovartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Capivasertib

AstraZeneca

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

59

clinical trials

Completed53 · 90%
Recruiting4 · 7%
Not yet recruiting2 · 3%

Clinical Trials

Trial Activity

59 trials

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants
Recruiting·Eisai logoEisai·Phase 1·NCT04271488·18 enrolled
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Recruiting·EExelixis·Phase 1·NCT06962332·20 enrolled
Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
Recruiting·AAligos Therapeutics·Phase 1·NCT07342868·16 enrolled
A Phase I, Single-dose, Non-randomized, Open-label, Parallel Group Study to Assess the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
Recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT07343960·20 enrolled
MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function
Not yet recruiting·LLykos Therapeutics·Phase 1·NCT03606538·16 enrolled
Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)
Not yet recruiting·Merck & Co. logoMerck & Co.·Phase 1·NCT05093972·22 enrolled
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group
Completed·Astellas logoAstellas·Phase 1·NCT01901133·33 enrolled
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
Completed·Eisai logoEisai·Phase 1·NCT02859207·32 enrolled
A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
Completed·AAgios Pharmaceuticals, Inc.·Phase 1·NCT03282513·33 enrolled
The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function
Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT06562946·24 enrolled
To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
Completed·CCerevel Therapeutics, LLC·Phase 1·NCT05404529·32 enrolled
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
Completed·AAgios Pharmaceuticals, Inc.·Phase 1·NCT05610657·20 enrolled
Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment
Completed·VVanda Pharmaceuticals·Phase 1·NCT01271387·29 enrolled
Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment
Completed·MMylan Inc.·Phase 1·NCT02581592·16 enrolled
Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects
Completed·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Phase 1·NCT01888393·23 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)